

# **NEW RAY MEDICINE INTERNATIONAL HOLDING LIMITED**

*(Incorporated in Bermuda with limited liability)*

(the “**Company**”)

## **PROCEDURES FOR SHAREHOLDERS TO PROPOSE A PERSON FOR ELECTION AS DIRECTOR**

Pursuant to Rule 17.50C of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”), the Company sets out the procedures, as governed by the Company’s bye-laws (“**Bye-laws**”), for shareholders to propose a person for election as a director of the Company (“**Director**”).

Bye-law 85 of the Bye-laws provides that no person other than a Director retiring at the meeting shall, unless recommended by the Directors for election, be eligible for election as a Director at any general meeting unless a written notice signed by a shareholder (other than the person to be proposed) duly qualified to attend and vote at the meeting for which such notice is given of his intention to propose such person for election and a written notice signed by the person to be proposed of his willingness to be elected shall have been lodged at the head office or at the registration office of the Company and the length of period, during which such notice(s) are given, shall be the seven day period following the despatch of the notice of the general meeting appointed for such election (or such other period for the lodgment of such written notice(s) as may be determined by the Directors from time to time, provided that such other period shall be at least seven days, commencing no earlier than the day after the despatch of the notice of the general meeting and end no later than seven days prior to the date appointed for such general meeting).

Accordingly, if a shareholder of the Company wishes to propose a person other than a Director for election as a Director at the Company’s general meeting (“**Proposal**”), he/she should lodge a written notice setting out the Proposal with his/her contact details (e.g. name and address) clearly stated in an eligible manner, validity of which is subject to verification and confirmation by the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, according to its records, at the head office of the Company at Room 3702-03, Dikai International Centre, Hangzhou City, Zhejiang Province, the People’s Republic of China for the attention of the Company Secretary.

In addition, the aforesaid notice should be accompanied by (a) the biographical details referred to in Rule 17.50(2) of the GEM Listing Rules and such other information (e.g. contact details including residential address and telephone number(s), and Hong Kong Identity card/ passport number) of the proposed Director and (b) a written notice signed by the proposed Director confirming his/her willingness to be elected, the accuracy and completeness of his/her biographical details to be disclosed under Rule 17.50(2) of the GEM Listing Rules and his/her consent to the disclosure by the Company of his/her biographical details in accordance with the requirements of the GEM Listing Rules.

Upon receipt of the above notices, the Company shall publish an announcement or issue a supplemental circular to members of the Company in accordance with the requirements of the GEM Listing Rules, in each case containing, amongst others, the biographical details of the proposed Director.

This procedure is subject to review by the Board from time to time and shall be posted on the Company’s website at [www.newraymedicine.com](http://www.newraymedicine.com).

*Note: Shareholders may refer to Rule 17.50(2) of the GEM Listing Rules available on the website of The Stock Exchange of Hong Kong Limited at <http://www.hkex.com.hk>.*